Please assess the completion status of the following clinical trial:

Trial Title: Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- type 2 diabetic patients who had body mass index (BMI) ≥ 30 kg/m2 , were treated with metformin alone and had ages ranging from 18 to 60 years.~Exclusion Criteria:~* patients who had any other inflammatory disease~* patients with cardiovascular,~* patients with asthma~* patients with severe hepatic~* patients with renal disease,~* patients with epilepsy~* pregnant or lactating females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): 50 patients will receive metformin up to 2000mg/daily (Control group)
- Montelukast group (Type: EXPERIMENTAL): 50 patients will receive a combination of metformin up to 2000 mg/daily and montelukast (10 mg /day).

Based on this trial design, predict the completion outcome and termination type (if applicable).